Group One Trading, L.P. Rigel Pharmaceuticals Inc Transaction History

Group One Trading, L.P.

$2.4 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.72 - $1.56 $72 - $156	-100 Reduced 2.01%	4,880 $7,000
Q3 2023 Nov 09, 2023	BUY	$1.07 - $1.39 $5,328 - $6,922	4,980 New	4,980 $5,000
Q4 2022 Feb 09, 2023	SELL	$0.67 - $11.9 $26,689 - $474,036	-39,835 Reduced 78.16%	11,133 $16,000
Q3 2022 Nov 09, 2022	BUY	$1.1 - $12.2 $7,022 - $77,884	6,384 Added 14.32%	50,968 $60,000
Q2 2022 Aug 11, 2022	SELL	$0.67 - $3.19 $6,666 - $31,740	-9,950 Reduced 18.25%	44,584 $50,000
Q1 2022 May 12, 2022	SELL	$2.22 - $3.45 $138,061 - $214,555	-62,190 Reduced 53.28%	54,534 $163,000
Q4 2021 Feb 11, 2022	SELL	$2.36 - $3.57 $15,736 - $23,804	-6,668 Reduced 5.4%	116,724 $309,000
Q3 2021 Nov 12, 2021	BUY	$3.5 - $4.5 $353,591 - $454,617	101,026 Added 451.69%	123,392 $448,000
Q2 2021 Aug 10, 2021	BUY	$3.09 - $4.54 $69,110 - $101,541	22,366 New	22,366 $97,000
Q1 2021 May 12, 2021	SELL	$3.35 - $4.93 $143,520 - $211,211	-42,842 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$2.35 - $3.74 $100,678 - $160,229	42,842 New	42,842 $150,000
Q2 2019 Aug 09, 2019	SELL	$2.02 - $2.61 $169,473 - $218,973	-83,898 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$2.0 - $2.65 $163,066 - $216,062	81,533 Added 3447.48%	83,898 $216,000
Q4 2018 Feb 06, 2019	BUY	$2.08 - $3.36 $4,919 - $7,946	2,365 New	2,365 $5,000
Q1 2018 May 11, 2018	SELL	$3.54 - $4.54 $29,516 - $37,854	-8,338 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$3.23 - $4.3 $11,628 - $15,480	3,600 Added 75.98%	8,338 $32,000
Q3 2017 Nov 15, 2017	SELL	$2.18 - $2.57 $1,962 - $2,313	-900 Reduced 15.96%	4,738 $12,000
Q2 2017 Aug 14, 2017	BUY	N/A	5,638	5,638 $15,000

Others Institutions Holding RIGL

# of Institutions

Shares Held

334K

Call Options Held

Put Options Held

View Full List

About RIGEL PHARMACEUTICALS INC

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.81B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

More about RIGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.

Account